{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:15Z","timestamp":1788865995519,"version":"build-2803163510"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00198-026-08074-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:29:44Z","timestamp":1780392584000},"page":"1407-1408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to: Letter to the editor regarding: Real\u2011world rebound pattern of serum collagen type I C\u2011telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment\u2011induced bone loss"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3965-5295","authenticated-orcid":false,"given":"Federico","family":"Aldegheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-2293","authenticated-orcid":false,"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-5655","authenticated-orcid":false,"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"8074_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body J-J, Rodriguez EG, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B (2021) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106:264\u2013281. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"8074_CR2","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","volume":"109","author":"G Grassi","year":"2024","unstructured":"Grassi G, Ghielmetti A, Zampogna M, Chiodini I, Arosio M, Mantovani G, Eller-Vainicher C (2024) Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion? J Clin Endocrinol Metab 109:e1817\u2013e1826. https:\/\/doi.org\/10.1210\/clinem\/dgae224","journal-title":"J Clin Endocrinol Metab"},{"key":"8074_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-026-07936-4","author":"F Aldegheri","year":"2026","unstructured":"Aldegheri F, Fassio A, Appoloni M, Rotta D, Ruzzon F, Bertelle D, Adami G, Gatti D, Rossini M, Viapiana O (2026) Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone loss. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-026-07936-4","journal-title":"Osteoporos Int"},{"key":"8074_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00198-025-07798-2","volume":"37","author":"G Marcucci","year":"2026","unstructured":"Marcucci G, Biver E, Body JJ, Campusano C, Cannata-And\u00eda J, Confavreux C, De Villiers TJ, Ebeling PR, Hadji P, Kendler D, El Maghraoui A, Napoli N, Veronesi P, Rizzoli R, Brandi ML (2026) Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next? Osteoporos Int 37:341\u2013360. https:\/\/doi.org\/10.1007\/s00198-025-07798-2","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08074-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:45Z","timestamp":1788865425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08074-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["8074"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08074-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients provided consent for publication of anonymized data.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.V. declares advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Ely-Lilly, UCB, AbbVie, MSD, and BMS outside the submitted work.\u00a0M.R. reports advisory board honoraria, consultancy fees and\/or speaker fees from GSK, ItalFarmaco, Theramex, Janssen-Cilag, UCB, outside the submitted work.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}